| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BAUDAX BIO Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 23,000 | +0,44 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| SOLIGENIX | 1,130 | +9,18 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen | |
| CHARLOTTES WEB | 0,394 | +2,60 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results | Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,916 | -3,57 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) | - ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,725 | +7,41 % | XFRA B9P0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 0,831 | +2,56 % | Allarity Therapeutics, Inc.: Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment | This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded... ► Artikel lesen | |
| AVENUE THERAPEUTICS | 0,454 | 0,00 % | AVENUE THERAPEUTICS, INC. - 8-K, Current Report | ||
| BIOSTAR PHARMACEUTICALS | - | - | Biostar Pharma, Inc.: Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases | SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Cod e: 2563.HK)... ► Artikel lesen | |
| APTORUM GROUP | 0,840 | +13,47 % | Aptorum Group Ltd - 6-K, Report of foreign issuer | ||
| PETROS PHARMACEUTICALS | 0,066 | 0,00 % | Petros Pharmaceuticals, Inc. - 8-K, Current Report | ||
| PRF TECHNOLOGIES | 2,970 | +388,65 % | PRF Technologies Ltd. - 6-K, Report of foreign issuer | ||
| PROCESSA PHARMACEUTICALS | 2,430 | +11,98 % | RedChip Companies, Inc.: Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA)... ► Artikel lesen | |
| CDT EQUITY | 1,100 | +8,91 % | XFRA ZK70: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCDT EQUITY NEW DL-... ► Artikel lesen | |
| BAYER | 45,800 | +2,20 % | Bayer: Das wird der zukünftige Top-Seller | Der DAX-Konzern Bayer hat in den zurückliegenden Quartalen mit vielen guten Neuigkeiten aus der Pharma-Sparte bei den Anlegern punkten können. Die Leverkusener befinden sich in einer guten Position... ► Artikel lesen | |
| NOVO NORDISK | 40,310 | +0,01 % | Novo Nordisk Aktie: Aufgepasst, denn es wird spannend! Das Golden Cross rückt näher! | © Foto: 2026 Novo Nordisk A/SDie Novo Nordisk-Aktie steht vor einem entscheidenden charttechnischen Signal. Nach dem brutalen Absturz könnte sich das Blatt wenden. Der Kurs kämpft sich zurück, die wichtigen... ► Artikel lesen |